Premium
Ovarian cancers related to minimal access surgery
Author(s) -
Crawford Robin A. F.,
Gore Martin E.,
Shepherd John H.
Publication year - 1995
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1995.tb11431.x
Subject(s) - medicine , contraindication , referral , surgery , ovarian cancer , cancer , adnexal mass , adnexal diseases , incidence (geometry) , general surgery , laparoscopy , pathology , physics , alternative medicine , family medicine , optics
Objective To review the clinical features of women with ovarian cancer on whom minimal access surgery has been performed and to determine guidelines for the safe use of minimal access surgery for adnexal masses. Design Postal survey of members of the British Gynaecological Cancer Society (BGCS) and retrospective case review. Results BGCS consultants used ultrasound scanning (70%) and serum CA‐125 estimations (53%) prior to adnexal mass surgery. The membership felt that adnexal masses with solid elements, diameter greater than 8 cm, multi‐ocular or bilateral cysts or increased blood flow on Doppler scanning should not be operated on by minimal access surgery. A positive family history was also considered to be a contraindication. A total of 29 cases of ovarian cancer were identified on whom MAS had been performed. The incidence of cases was 4.1% of referrals to a tertiary referral centre (the Royal Marsden Hospital). The median age of patients was 37 years (range 20 to 68 years) and 13 had Stage I cancers. The mean delay between diagnosis and staging was 6.5 weeks. Conclusion Guidelines on the use of minimal access surgery in the management of adnexal masses need to be agreed. Women who have an ovarian cancer diagnosed whilst having minimal access surgery should have an accepted staging procedure. We do not recommend the routine use of minimal access surgery for the treatment of ovarian cancer outside a trial.